Risk of second malignancies in survivors of retinoblastoma: More than 40 years of follow-up

Journal of the National Cancer Institute

Volumn 100, Issue 24, 2008, Pages 1771-1779

  Marees, Tamara ^a   Moll, Annette C ^a   Imhof, Saskia M ^a   De Boer, Michiel R ^b   Ringens, Peter J ^a   Van Leeuwen, Flora E ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; RETINOBLASTOMA 1 PROTEIN; RETINOBLASTOMA PROTEIN; TRETAMINE; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; CANCER SURVIVOR; FAMILIAL CANCER; FOLLOW UP; GENE MUTATION; HUMAN; LUNG CANCER; NETHERLANDS; PRIORITY JOURNAL; RETINOBLASTOMA; SECOND CANCER;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; CONFIDENCE INTERVALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, SECOND PRIMARY; NETHERLANDS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; REGISTRIES; RETINAL NEOPLASMS; RETINOBLASTOMA; RETINOBLASTOMA PROTEIN; RISK ASSESSMENT; RISK FACTORS; SURVIVORS; TIME FACTORS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 58049202910     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn394     Document Type: Article

References (43)

1. Knudson AG Jr, Meadows AT, Nichols WW, Hill R. Chromosomal deletion and retinoblastoma. N Engl J Med. 1976;295(20):1120-1123.
2. Shonkwiler R, Mistretta M, Varma V. A growth and division model for retinoblastoma. Math Biosci. 2008;211(2):255-264.
3. Vogel F. Genetics of retinoblastoma. Hum Genet. 1979;52(1):1-54.
4. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23(10):2272-2279.
5. Moll AC, Imhof SM, Bouter LM, et al. Second primary tumors in patients with hereditary retinoblastoma: a register-based follow-up study, 1945-1994. Int J Cancer. 1996;67(4):515-519.
6. Forrest AW. Tumors following radiation about the eye. Trans Am Acad Ophthalmol Otolaryngol. 1961;65(5):694-717.
7. Imhof SM, Moll AC, Hofman P, Mourits MP, Schipper J, Tan KE. Second primary tumours in hereditary- and nonhereditary retinoblastoma patients treated with megavoltage external beam irradiation. Doc Ophthalmol. 1997;93(4):337-344.
8. Reese A, Merriam G, Martin H. Treatment of bilateral retinoblastoma by irradiation and surgery: report on fifteen years results. Am J Ophthalmol. 1949;32(2):175-190.
9. Soloway HB. Radiation-induced neoplasms following curative therapy for retinoblastoma. Cancer. 1966;19(12):1984-1988.
10. Abramson DH, Ronner HJ, Ellsworth RM. Second tumors in nonirradiated bilateral retinoblastoma. Am J Ophthalmol. 1979;87(5):624-627.
11. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85(14):1121-1128.
12. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278(15):1262-1267.
13. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53(5):661-671.
14. DerKinderen DJ, Koten JW, Nagelkerke NJ, Tan KE, Beemer FA, Den Otter W. Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int J Cancer. 1988;41(4):499-504.
15. Desjardins L, Haye C, Schlienger P, Laurent M, Zucker JM, Bouguila H. Second non-ocular tumours in survivors of bilateral retinoblastoma. A 30-year follow-up. Ophthalmic Paediatr Genet. 1991;12(3):145-148.
16. Fletcher O, Easton D, Anderson K, Gilham C, Jay M, Peto J. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst. 2004;96(5):357-363.
17. Kleinerman RA, Tucker MA, Abramson DH, Seddon JM, Tarone RE, Fraumeni JF Jr. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 2007;99(1):24-31.
18. Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology. 1988;95(11):1583-1587.
19. DerKinderen DJ, Koten JW, Wolterbeek R, Beemer FA, Tan KE, Den Otter W. Non-ocular cancer in hereditary retinoblastoma survivors and relatives. Ophthalmic Paediatr Genet. 1987;8(1):23-25.
20. Schappert-Kimmijser J, Hemmes GD, Nijland R. The heredity of retinoblastoma. Ophthalmologica. 1966;151 (2):197-213.
21. Moll AC, Kuik DJ, Bouter LM, et al. Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862-1995. Br J Ophthalmol. 1997;81(7):559-562.
22. Guldberg P, Güttler F. A simple method for identification of point mutations using denaturing gardient gel electrophoresis. Nucleic Acids Res. 1993;21(9):2261-2262.
23. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiples ligation-dependent probe amplification. Nucleic Acids Res. 2002;30(12):e57.
24. World Health Organisation. International Classification of Diseases for Oncology. 2nd ed. Geneva, Switzerland: WHO; 1990.
25. Muir C, Waterhouse J, Mack T. Cancer incidents in five continents. IARC Sci Publ. 1987;5(88):1-970.
26. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents. Volume VII. Lyon, France: International Agency for Research on Cancer; 1997.
27. van der Sanden GA, Coebergh JW, Schouten LJ, Visser O, van Leeuwen FE. Cancer incidence in the Netherlands in 1989 and 1990: first results of the nationwide Netherlands cancer registry. Coordinating Committee for Regional Cancer Registries. Eur J Cancer. 1995;31A(11):1822-1829.
28. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol. 1994;12(2):312-325.
29. Pearson ES, Hartley HO, eds. Biometrika Tables for Statisticians. London, UK: Biometrika Trust; 1976.
30. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
31. Jakobiec FA, Tso MO, Zimmerman LE, Danis P. Retinoblastoma and intracranial malignancy. Cancer. 1977;39(5):2048-2058.
32. Visser O, Siesling S, van Dijck JAAM, eds. Incidence of Cancer in the Netherlands, 1999/2000. Utrecht, the Netherlands: Vereniging van Integrale Kanker Centra; 2003.
33. Abramson DH, Ellsworth RM, Kitchin FD, Tung G. Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced? Ophthalmology. 1984;91(11):1351-1355.
34. Knudson AG Jr. Retinoblastoma: a prototypic hereditary neoplasm. Semin Oncol. 1978;5(1):57-60.
35. Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317(10):588-593.
36. Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 2007;26(1):1-18.
37. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer. 2003;3(9):685-694.
38. Moll AC, Imhof SM, Bouter LM, Tan KE. Second primary tumors in patients with retinoblastoma. A review of the literature. Ophthalmic Genet. 1997;18(1):27-34.
39. Kannan K, Sharpless NE, Xu J, O'Hagan RC, Bosenberg M, Chin L. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci USA. 2003;100(3):1221-1225.
40. Yang G, Rajadurai A, Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol. 2005;125(6):1242- 1251.
41. Horowitz JM, Park SH, Bogenmann E, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA. 1990;87(7):2775-2779.
42. Kleinerman RA, Tarone RE, Abramson DH, Seddon JM, Li FP, Tucker MA. Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst. 2000;92(24):2037-2039.
43. Mitra AP, Birkhahn M. Cote RJ. p53 and retinoblastoma pathways in bladder cancer. World J Urol. 2007;25(6):563-571.